Overview
- AstraZeneca discontinued the eVOLVE‑Lung02 trial after an independent data monitoring committee on Monday, August 17, 2026 recommended stopping the study for futility in the prespecified PD‑L1 <1% population.
- The IDMC found the volrustomig plus chemotherapy arm was unlikely to achieve the trial’s dual primary endpoints of progression‑free survival and overall survival in PD‑L1 negative patients.
- The company reported no new safety signals, said the safety profile matched known effects of the individual agents, and pledged to work with investigators to ensure continuity of care and follow‑up for enrolled patients.
- The global study had enrolled 895 patients across 25 countries before it was halted, and AstraZeneca said other Phase III volrustomig trials in cervical cancer, head and neck cancer, and mesothelioma will proceed.
- AstraZeneca also released positive late‑stage data for Enhertu and a Tagrisso combination the same day, producing modest stock gains but adding to wider 2026 scrutiny of the company’s pipeline as investors await results from the remaining volrustomig programs and upcoming regulatory steps.